Acamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor modulator approved by the Food and Drug Administration (FDA) as a pharmacological treatment for alcohol dependence.Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||10mM in water|
Acamprosate produces its anti-relapse effects via calcium.
Spanagel R, et al. Neuropsychopharmacology. 2014 Mar;39(4):783-91. PMID: 24081303.
|Related GABA Receptor Products|
Zuranolone also known as SAGE-217, is a potent GABAA receptor agonist with EC50 values of 296 nM and 163 nM for α1β2γ2 and α4β3δ GABAA receptors.
SSD114 hydrochloride is a GABAB receptor positive allosteric modulator.
Pipequaline (PK-8165) is a partial benzodiazepine receptor agonist with anxiolytic activity.
AZD-7325 is a GABA-Aα2,3 -selective receptor modulator.
ONO-8590580 is a GABAAα5 negative allosteric modulator which enhances long-term potentiation and improves cognitive deficits in preclinical models.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.